Yarrow Bioscience Inc. (YARW) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, YARW scores 41 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 5/20 (ROIC -35%; FCF yield -17.8%), Whale 13F Flow at 12/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 11/20 (Altman Z 9.31; Piotroski F 3/9; Debt/Equity 0.5). The weakest pillars are Insider Conviction and Fundamental Cash Engine, which together indicate that the company is consuming cash without generating operating returns, and that insider signal flow is weak. The strongest pillar is Whale 13F Flow, which indicates some institutional positioning activity, though the source data does not itemize the holders. For a prospective investor, the rating implies that valuation support must come from future operating progress rather than current cash generation, and that the company's reported losses are the central tradeoff to weigh against any upside thesis. The forensic balance sheet score being mid-range rather than strong means the company is not in an obvious solvency crisis per these metrics, but it is also not a high-quality financial profile.

Yarrow Bioscience Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The source data does not describe its products, customers, or revenue model. Reported revenue is small, at $0.6M for FY 2025, per the SEC financials. The profile identifies the company as having a market capitalization of $0.2B.

Per the SEC financials, the company reported operating losses in each period shown, with FY 2025 operating income at $-29.7M against revenue of $0.6M. Per the market data, the operating margin, net margin, and gross margin are -60%, -60%, and 0% respectively, and ROIC is -35%. The Altman Z-Score of 9.31 and Piotroski F-Score of 3/9 are cited in the Roarable RQD rating, and the Debt/Equity ratio is 0.5. Cash rose from $19.9M in FY 2024 to $24.0M in FY 2025 per the SEC financials. Debt is not available in source data.

Per the recent news and catalysts feed, the most recent items are a TradingView estimates report and a Simply Wall St stock analysis, both flagged YELLOW under the Market Wire category. A Stock Titan item flagged RED under Risk Watch reports a Boston fireside chat webcast. Additional Stock Titan items report executive option grants: a COO option award of 89,844 shares at a $20 exercise price, an award of 99,827 shares at $20 each to Lori Payton, and a CEO option award of 465,857 options at a $20 exercise price to Rebecca Frey. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The source data therefore does not establish upstream suppliers, downstream customers, or sector correlation links. An investor should note that the absence of mapped links means second-order ripple effects cannot be assessed from the provided data.

• What are the company's products, clinical or commercial programs, and revenue sources, given that the profile does not describe them?
• What is the debt position, since debt is listed as N/A across all reported periods?
• What is the reason for the absence of EPS and forward estimates, and what is the cash runway implied by FY 2025 cash of $24.0M against FCF of $-33.1M?
• Who are the institutional holders and insiders behind the Whale 13F and Insider Conviction pillar scores?
• What do the executive option grants at a $20 exercise price signal relative to the current $19.9 price?